[From nobody Sat Feb 18 11:22:56 2006
Date: Wed, 13 Aug 1997 10:36:11 EST
From: "John Wynne"@A1.TCH.HARVARD.EDU
Subject: - no subject (01IME36PCO8M9XU9W1) -
Sender: "leish-l@bdt.org.br" <leish-l@bdt.org.br>
To: Multiple recipients of list <leish-l@bdt.org.br>
Reply-to: "leish-l@bdt.org.br" <leish-l@bdt.org.br>
Message-id: <01IME36PCO8K9XU9W1@LEILA.TCH.HARVARD.EDU>
Content-type: TEXT/PLAIN
Posting-date: Wed, 13 Aug 1997 12:28:03 EST
Importance: normal
X400-MTS-identifier: [;30822131807991/6626619@HUB]
A1-type: MAIL

Does anyone have any experience or knowledge of the company CORIXA. They 
are developing vaccines and diagnostics based on antigens and adjuvants to 
stimulate T-cells in Leishmaniasis (and T. cruzii).

Any information or opinions you can share about the technology, company or 
opportunity would be most helpful. Thank you.

]